Aerovate Q2 net loss $19.0M; cash $150.1M; ATM raised $45M; Phase 2b/3 PAH trial on track

Jade Biosciences, Inc.

2023-Q2 EPS reported -$1.42

Net loss of $19.0M for Q2 2023 vs $12.0M in Q2 2022; includes $3.0M stock comp.
Cash, cash equivalents and available-for-sale securities total $150.1M; runway extended into 2026.
Sold $45M common stock under ATM program; proceeds fund operations.
IMPAHCT Phase 2b/Phase 3 trial for AV-101 in PAH has >110 sites active in >20 countries; topline data expected Q2 2024.
Appointed Habib Dable (ex-Acceleron CEO) to Board of Directors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Jade Biosciences, Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended June 30, 2023, and recent business highlights.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Jade Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001798749-23-000053

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.